 Vascular Endothelial Growth Factor Receptor-2
"Vascular Endothelial Growth Factor Receptor-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 200-230-kDa tyrosine kinase receptor for vascular endothelial growth factors found primarily in endothelial and hematopoietic cells and their precursors. VEGFR-2 is important for vascular and hematopoietic development, and mediates almost all endothelial cell responses to VEGF.
| Descriptor ID |
D040301
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.950.200 D12.776.543.750.630.750.200 D12.776.543.750.750.400.910.200
|
| Concept/Terms |
Vascular Endothelial Growth Factor Receptor-2- Vascular Endothelial Growth Factor Receptor-2
- Vascular Endothelial Growth Factor Receptor 2
- KDR Tyrosine Kinase
- Tyrosine Kinase, KDR
- VEGFR-2
- Fetal Liver Kinase-1
- Fetal Liver Kinase 1
- Kinase Insert Domain Receptor
- VEGF Receptor Flk-1
- Flk-1, VEGF Receptor
- VEGF Receptor Flk 1
- VEGF Receptor KDR
- KDR, VEGF Receptor
- Flk-1 Protein
- Flk 1 Protein
- Flk-1 Receptor Tyrosine Kinase
- Flk 1 Receptor Tyrosine Kinase
|
Below are MeSH descriptors whose meaning is more general than "Vascular Endothelial Growth Factor Receptor-2".
Below are MeSH descriptors whose meaning is more specific than "Vascular Endothelial Growth Factor Receptor-2".
This graph shows the total number of publications written about "Vascular Endothelial Growth Factor Receptor-2" by people in this website by year, and whether "Vascular Endothelial Growth Factor Receptor-2" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 3 | 4 | | 2005 | 1 | 3 | 4 | | 2006 | 1 | 3 | 4 | | 2007 | 0 | 5 | 5 | | 2008 | 2 | 2 | 4 | | 2009 | 0 | 2 | 2 | | 2010 | 2 | 3 | 5 | | 2011 | 0 | 2 | 2 | | 2012 | 1 | 1 | 2 | | 2013 | 1 | 5 | 6 | | 2014 | 1 | 1 | 2 | | 2015 | 2 | 1 | 3 | | 2016 | 1 | 0 | 1 | | 2018 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Vascular Endothelial Growth Factor Receptor-2" by people in Profiles.
-
Slagle CJ, Thamm DH, Randall EK, Borden MA. Click Conjugation of Cloaked Peptide Ligands to Microbubbles. Bioconjug Chem. 2018 05 16; 29(5):1534-1543.
-
Grabowski J, Glode A. Ramucirumab: A vascular endothelial growth factor receptor-2 inhibitor with activity in several malignancies. Am J Health Syst Pharm. 2016 Jul 01; 73(13):957-68.
-
Delaney C, Wright RH, Tang JR, Woods C, Villegas L, Sherlock L, Savani RC, Abman SH, Nozik-Grayck E. Lack of EC-SOD worsens alveolar and vascular development in a neonatal mouse model of bleomycin-induced bronchopulmonary dysplasia and pulmonary hypertension. Pediatr Res. 2015 Dec; 78(6):634-40.
-
Scott AJ, Messersmith WA, Jimeno A. Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors. Drugs Today (Barc). 2015 Apr; 51(4):223-9.
-
Kumar R, Deep G, Wempe MF, Agarwal R, Agarwal C. Procyanidin B2 3,3?-di-O-gallate inhibits endothelial cells growth and motility by targeting VEGFR2 and integrin signaling pathways. Curr Cancer Drug Targets. 2015; 15(1):14-26.
-
Song EK, Tai WM, Messersmith WA, Bagby S, Purkey A, Quackenbush KS, Pitts TM, Wang G, Blatchford P, Yahn R, Kaplan J, Tan AC, Atreya CE, Eckhardt G, Kelley RK, Venook A, Kwak EL, Ryan D, Arcaroli JJ. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. Int J Cancer. 2015 Apr 15; 136(8):1967-75.
-
Howell KR, Pillai A. Effects of prenatal hypoxia on schizophrenia-related phenotypes in heterozygous reeler mice: a gene × environment interaction study. Eur Neuropsychopharmacol. 2014 Aug; 24(8):1324-36.
-
McKenna S, Michaelis KA, Agboke F, Liu T, Han K, Yang G, Dennery PA, Wright CJ. Sustained hyperoxia-induced NF-?B activation improves survival and preserves lung development in neonatal mice. Am J Physiol Lung Cell Mol Physiol. 2014 Jun 15; 306(12):L1078-89.
-
Grivas PD, Daignault S, Tagawa ST, Nanus DM, Stadler WM, Dreicer R, Kohli M, Petrylak DP, Vaughn DJ, Bylow KA, Wong SG, Sottnik JL, Keller ET, Al-Hawary M, Smith DC, Hussain M. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer. 2014 Mar 01; 120(5):692-701.
-
Janssen WJ, Yunt ZX, Muldrow A, Kearns MT, Kloepfer A, Barthel L, Bratton DL, Bowler RP, Henson PM. Circulating hematopoietic progenitor cells are decreased in COPD. COPD. 2014 Jun; 11(3):277-89.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|